首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2347100篇
  免费   175204篇
  国内免费   3376篇
耳鼻咽喉   32168篇
儿科学   75969篇
妇产科学   62794篇
基础医学   348370篇
口腔科学   63749篇
临床医学   211295篇
内科学   456888篇
皮肤病学   51816篇
神经病学   185339篇
特种医学   88155篇
外国民族医学   490篇
外科学   354270篇
综合类   47591篇
现状与发展   13篇
一般理论   849篇
预防医学   182579篇
眼科学   54296篇
药学   175213篇
  9篇
中国医学   4631篇
肿瘤学   129196篇
  2021年   19068篇
  2019年   19611篇
  2018年   27155篇
  2017年   20437篇
  2016年   22829篇
  2015年   25738篇
  2014年   36231篇
  2013年   54105篇
  2012年   74936篇
  2011年   79668篇
  2010年   47206篇
  2009年   44662篇
  2008年   74775篇
  2007年   79687篇
  2006年   80483篇
  2005年   77993篇
  2004年   74516篇
  2003年   71840篇
  2002年   69531篇
  2001年   108817篇
  2000年   111534篇
  1999年   93586篇
  1998年   27017篇
  1997年   23686篇
  1996年   24077篇
  1995年   22742篇
  1994年   20909篇
  1993年   19722篇
  1992年   72035篇
  1991年   70102篇
  1990年   68414篇
  1989年   65689篇
  1988年   60329篇
  1987年   59148篇
  1986年   55239篇
  1985年   53029篇
  1984年   39323篇
  1983年   33406篇
  1982年   19863篇
  1979年   35877篇
  1978年   25657篇
  1977年   21232篇
  1976年   20335篇
  1975年   21824篇
  1974年   26167篇
  1973年   24808篇
  1972年   23205篇
  1971年   22048篇
  1970年   20262篇
  1969年   19324篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
11.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy  相似文献   
12.
13.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
14.
15.
16.
BackgroundTotal hip and knee arthroplasties are increasingly performed operations, and routine follow-up places huge demands on orthopedic services. This study investigates the effectiveness, patients’ satisfaction, and cost reduction of Virtual Joint Replacement Clinic (VJRC) follow-up of total hip arthroplasty and total knee arthroplasty patients in a university hospital. VJRC is especially valuable when in-person appointments are not advised or feasible such as during the COVID-19 pandemic.MethodsA total of 1749 patients who were invited for VJRC follow-up for knee or hip arthroplasty from January 2017 to December 2018 were included in this retrospective study. Patients were referred to VJRC after their 6-week postoperative review. Routine VJRC postoperative review was undertaken at 1 and 7 years and then 3-yearly thereafter. We evaluated the VJRC patient response rate, acceptability, and outcome. Patient satisfaction was measured in a subgroup of patients using a satisfaction survey. VJRC costs were calculated compared to face-to-face follow-up.ResultsThe VJRC had a 92.05% overall response rate. Only 7.22% required further in-person appointments with only 3% being reviewed by an orthopedic consultant. VJRC resulted in an estimated saving of £42,644 per year at our institution. The patients’ satisfaction survey showed that 89.29% of the patients were either satisfied or very satisfied with VJRC follow-up.ConclusionVJRC follow-up for hip and knee arthroplasty patients is an effective alternative to in-person clinic assessment which is accepted by patients, has high patient satisfaction, and can reduce the cost to both health services and patients.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号